Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: AZN.LSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

AstraZeneca (AZN) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

13,257 GBX

+6.1%+8.3% incl. dividends

2031

5-Year

BUY

17,943 GBX

+43.5%+59.3% incl. dividends

Published batch insight

Biopharma Pipeline Replacement Velocity Collides With Severe Statutory Pricing Pressures

Consensus reflects sharp divergence between headline revenue targets and statutory cash conversion. Robust oncology expansion and rare-disease durability offset imminent Farxiga patent cliffs, but elevated clinical capital intensity and sovereign price negotiations constrain multiple expansion, anchoring an earnings-led rather than valuation-driven trajectory.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Sherlock Holmes (Whistleblower), Superintelligence (Anthropologist), Universal Investor (Polymath), Elon Musk (Visionary), Ray Dalio (Strategist), Warren Buffett (Value Purist), Machiavelli (Insider), J.P. Morgan (Titan), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in AstraZeneca at the forecast anchor (2026-09-18): $15,721 in five years versus $13,892 for S&P 500 benchmark.

AstraZeneca · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 2.1% net dividend yield for AstraZeneca.

Figure: Five-year synthesized consensus value path for AstraZeneca compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in GBX; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 12,500 GBX1-year price return: +6.06%5-year price return: +43.54%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in GBX, with returns and rationale
Quarter	Target (GBX)	Quarter return	Total return	Forecast rationale
Q4 2026	12,651.62	+1.21%	+1.21%	Oncology volume expansion and rare-disease cash conversion counterbalance initial Farxiga pricing concessions. Defensive institutional rotation supports steady equity accumulation, though elevated research outlays and macro discount rates keep quarterly multiple appreciation measured.
Q1 2027	12,866.00	+1.69%	+2.93%	Full-year financial reporting confirms double-digit core earnings progression alongside initial tozorakimab regulatory filings. Strong commercial uptake in breast and lung cancer indications offsets localized emerging-market pricing headwinds, sustaining positive share performance.
Q2 2027	13,088.77	+1.73%	+4.71%	Expanding commercial contributions from newly approved therapies accelerate top-line replacement. However, US statutory pricing negotiations and European generic competition on legacy primary-care medicines impose modest gross margin friction, moderating intermediate quarterly gains.
Q3 2027	13,257.22	+1.29%	+6.06%	Congress presentations demonstrate sustained clinical efficacy across pivotal oncology pipelines. High-barrier rare-disease therapies generate resilient cash flows, insulating group operating profits from macroeconomic consolidation and supporting steady institutional sponsorship.
Q4 2027	13,600.93	+2.59%	+8.81%	Commercial rollouts of respiratory biologics and expanding antibody-drug conjugate indications drive volume growth. Cash generation comfortably absorbs heavy Phase III clinical trial commitments, reassuring allocators of underlying earnings durability into year-end.
Q1 2028	13,788.57	+1.38%	+10.31%	Annual financial disclosures validate operating leverage expansion despite peak Farxiga patent-loss headwinds. Solid cash conversion supports dividend progression, though election-year drug pricing rhetoric in major Western markets prevents substantive multiple expansion.
Q2 2028	14,091.16	+2.19%	+12.73%	Global label expansions for earlier-line solid tumor regimens broaden addressable patient populations. Incremental gross profit conversion outpaces fixed infrastructure cost growth, driving fundamental earnings upgrades across major international brokerages.
Q3 2028	14,376.89	+2.03%	+15.02%	Late-stage cardiometabolic and bispecific pipeline readouts reinforce the medium-term replacement trajectory. Defensive healthcare inflows and easing monetary policy discount rates provide valuation support, maintaining measured quarterly price appreciation.
Q4 2028	14,695.05	+2.21%	+17.56%	Manufacturing efficiencies across dedicated biologics facilities lower unit costs, bolstering operating margins. Positive clinical milestone deliveries cushion residual pricing drag, driving disciplined institutional positioning across high-quality pharmaceutical defensives.
Q1 2029	14,907.31	+1.44%	+19.26%	Full-year results demonstrate that top-line growth has overcome legacy patent cliffs, with group revenues expanding solidly. Free cash flow generation improves as peak facility capital expenditures begin moderating, supporting equity gains.
Q2 2029	15,239.96	+2.23%	+21.92%	Specialty oncology scaling drives operating margins higher, but approaching exclusivity horizons on older targeted biologics temper multiple expansion. The market balances accelerating cash generation against mid-horizon therapeutic life-cycle renewal obligations.
Q3 2029	15,520.77	+1.84%	+24.17%	Diversified commercial demand across respiratory, rare-disease, and targeted oncology segments maintains steady volume momentum. Inelastic healthcare spending insulates operating cash generation from wider European economic deceleration, sustaining modest price progress.
Q4 2029	15,928.91	+2.63%	+27.43%	Approaching long-range operational milestones, revenue visibility improves substantially. Maturing launch portfolios generate dependable operating cash flows, enabling balance-sheet deleveraging and funding selective pipeline licensing without equity dilution.
Q1 2030	16,173.75	+1.54%	+29.39%	Annual reporting confirms total group revenues approaching landmark thresholds, validating long-term corporate execution. While statutory payer discounting caps terminal margins, core earnings per share expansion delivers reliable equity support.
Q2 2030	16,524.18	+2.17%	+32.19%	Commercial maturation of next-generation oncology biologics drives operating cash flows to cyclical highs. Stable balance-sheet metrics allow management to broaden shareholder distributions, preserving defensive holding patterns across institutional registers.
Q3 2030	16,808.76	+1.72%	+34.47%	Share price consolidation reflects a balanced market weighing substantial multi-year earnings gains against scheduled patent transitions on legacy oncology blockbusters. Non-cyclical patient demand establishes a firm valuation floor.
Q4 2030	17,118.48	+1.84%	+36.95%	Closing out the decade, scaled biologic manufacturing and expanded global distribution cement market leadership. High cash conversion supports capital returns, delivering modest end-of-year price appreciation anchored in realized operating profits.
Q1 2031	17,395.86	+1.62%	+39.17%	Full-year disclosures confirm structural execution across twenty commercial blockbusters. While top-line growth settles into a mature low-double-digit cadence, strong cash generation preserves fundamental valuation multiples against sovereign debt yields.
Q2 2031	17,650.36	+1.46%	+41.20%	Early commercialization of next-generation modalities refreshes pipeline durability beyond mature product cliffs. Steady operating margins and dependable dividend accruals provide resilient equity returns during broader macroeconomic rotation.
Q3 2031	17,942.89	+1.66%	+43.54%	The five-year forecast concludes with the enterprise established as a high-barrier biopharmaceutical cash compounder. Normalized earnings yield, robust therapeutic moats, and self-funding innovation justify a firm valuation baseline.

AstraZeneca functions as an industrial-scale biopharmaceutical replacement engine rather than a passive defensive bond proxy. The base-case economic argument centers on whether commercial scaling across Daiichi Sankyo-partnered antibody-drug conjugates, respiratory biologics, and rare-disease franchises can outpace mechanical generic erosion from Farxiga and maturing oncology blockbusters. While top-line revenues track toward high-seventy-billion thresholds by 2030, free cash flow conversion will lag adjusted operating figures due to persistent capital absorption across clinical trials and onshore manufacturing buildouts. Valuation sensitivity remains tightly tethered to discount rates: in an environment of elevated sovereign yields, an entry multiple above twenty-five times trailing earnings limits multiple-driven rerating. The investment case rests on mid-to-high single-digit revenue expansion translating into low-double-digit core earnings growth.

Key insights

Partnered oncology assets deliver gross margin expansion, but shared licensing economics mean top-line blockbuster growth does not fully convert into distributable equity cash flow.
High-barrier rare-disease therapies provide vital cash flow inelasticity, effectively subsidizing an annual research and development capital intensity exceeding twenty-three percent of revenue.
Sovereign price controls and Medicare negotiations permanently compress late-cycle tail margins, shifting the terminal valuation basis toward volume delivery over pricing power.

Deep Dive

Outside market sentiment treats AstraZeneca as a premier European pharmaceutical compounder with visible top-line momentum, broadly endorsing management's aspirational eighty-billion-dollar 2030 revenue roadmap. Prevailing consensus relies on continuous oncology market share gains and rare-disease durability, assuming these high-margin pillars will effortlessly neutralize impending Farxiga patent cliffs, Chinese volume-based procurement cuts, and statutory Medicare price concessions.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates structural friction while overestimating intermediate cash conversion, establishing that shares are fairly priced to modestly underpriced on earnings compounding rather than valuation rescue. Market consensus erroneously conflates gross top-line replacement with net distributable cash flows, overlooking that shared partner economics, capital-intensive manufacturing, and statutory price caps suppress cash margins. The analytical edge lies in recognizing that quality volume growth will drive attractive long-term owner earnings once generic headwinds trough.

Repricing catalyst

Convergence requires consecutive reporting periods in 2027 demonstrating that core operating margin expansion and new launch volumes outpace Farxiga generic erosion. Pivotal Phase III readouts and regulatory approvals for tozorakimab in respiratory disease and datopotamab deruxtecan in lung cancer represent the primary operational triggers. Visible free cash flow conversion improvements will force sell-side models to de-risk medium-term cash forecasts.

Published consensus context

Macro regime alignment

The prevailing macro regime of higher-for-longer benchmark yields and persistent cost inflation presents a mixed backdrop. Elevated discount rates compress valuation multiples on long-duration clinical pipelines and raise debt refinancing expenses. However, non-cyclical, price-inelastic demand for vital oncology and rare-disease therapies provides exceptional revenue insulation, positioning the company as a defensive compounder during stagflationary periods.

Published consensus context

Advisor disagreement

The decisive disagreement across reports centers on terminal valuation multiples and the net cash conversion of the pipeline. Bullish perspectives argue that high-barrier biologics command durable monopoly pricing power, propelling core operating margins above 32% and justifying a premium multiple near twenty-four times forward earnings. Conversely, skeptical analyses emphasize that statutory price negotiations, partnered profit splits, and relentless clinical capital intensity will cap free cash flow yield near 3.5%, holding terminal multiples down around eighteen times. Resolving this tension requires tracking whether reported free cash flow accelerates alongside core operating earnings through 2027.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Antibody conjugate and oncology expansion: Commercial scaling of Daiichi Sankyo-partnered antibody-drug conjugates, particularly Enhertu and datopotamab deruxtecan, drives robust volume expansion across early-line breast and lung cancers. Superior progression-free survival data secures high-margin treatment lines, replacing maturing revenue and insulating top-line growth from primary-care patent expirations over the forecast window. Expected impact: +24%.
Alexion rare disease cash compounding: Patient migration from Soliris to long-acting Ultomiris alongside novel complement-inhibitor launches creates immense switching barriers in paroxysmal nocturnal hemoglobinuria. Inelastic therapeutic demand and orphan designations yield durable gross margins exceeding 85%, generating recurring operating cash flow that systematically funds late-stage pipeline investments without balance-sheet strain. Expected impact: +15%.
Respiratory biologic commercial lifecycle renewal: Phase III validation and regulatory submissions for tozorakimab in chronic obstructive pulmonary disease unlock a substantial addressable volume market across broad patient subgroups. Alongside Breztri and Tezspire, this portfolio renewal replaces expiring small-molecule inhaler revenues and preserves long-term specialty respiratory operating profitability. Expected impact: +14%.
Commercial infrastructure operating margin leverage: Leveraging established global sales infrastructure allows specialty oncology and biologic launches to scale without proportional selling and administrative expense growth. Rationalized post-acquisition distribution and automated manufacturing compress unit overhead, supporting core operating margin progression toward low-thirties percentages and compounding per-share cash earnings. Expected impact: +12%.

Top frictions and headwinds

Farxiga loss of exclusivity cliff: Loss of composition-of-matter patent protection on dapagliflozin across the United States and Europe triggers steep generic competition and rapid volume erosion. Stripping away an eight-billion-dollar high-margin pillar creates an acute earnings drag that requires substantial commercial contribution from newer therapies simply to stabilize segment profits. Expected impact: -15%.
Sovereign drug price negotiation compression: Implementation of mandatory Medicare maximum fair price negotiations under the Inflation Reduction Act alongside European reference pricing directly deflates net realized drug prices. Administrative pricing caps permanently truncate the tail-end cash flow of mature blockbusters, reducing terminal valuation multiples across AstraZeneca's primary geographic markets. Expected impact: -11%.
China regulatory scrutiny and procurement: Heightened legal oversight, executive indictments, and expanded Volume-Based Procurement in China suppress realized hospital margins across a market generating over 12% of revenue. Compulsory price reductions on off-patent portfolios and elevated local compliance costs dampen regional return on capital and slow international growth momentum. Expected impact: -9%.
Elevated clinical trial capital absorption: Sustaining over one hundred Phase III trials drives annual research and development spending above fourteen billion dollars, consuming roughly a quarter of sales. Escalating developmental complexity and clinical trial inflation dilute near-term free cash flow conversion, restricting aggressive share repurchase capacity and dividend expansion. Expected impact: -8%.

Tail risks

Severe ADC interstitial lung toxicity crisis: Unexpected clustering of drug-related interstitial lung disease or severe off-target toxicities in pivotal Phase III trials by 2027 could prompt regulatory clinical holds or black-box warnings. Such safety setbacks would immediately curtail prescribing adoption in earlier-line settings, vaporizing billions in projected peak oncology cash flows and triggering significant multiple contraction. Probability: +24%. Expected impact: -23%.
China systemic hospital procurement debarment: Escalation of Chinese criminal probes into formal corporate sanctions, severe financial penalties, or exclusion from the National Reimbursement Drug List by 2027 would sever major emerging-market revenues. Losing unencumbered hospital market access across China would strand local capital infrastructure, impair consolidated operating profits, and inflict severe structural multiple compression. Probability: +20%. Expected impact: -20%.

Tail opportunities

Oral GLP1 cardiometabolic registrational triumph: Phase III clinical validation of oral GLP-1 candidate elecoglipron demonstrating weight-loss efficacy and tolerability comparable to injectable peptides by 2028 would crack the massive metabolic market. Bypassing cold-chain manufacturing bottlenecks would generate billions in high-margin peak revenue, expanding cardiometabolic earnings and triggering aggressive multiple rerating across global desks. Probability: +30%. Expected impact: +24%.
Frontline pan tumor ADC standard displacement: Accelerated registrational approvals establishing datopotamab deruxtecan and next-generation bispecifics as unconstrained first-line standards of care in lung and breast cancer by 2028 would broadly displace conventional chemotherapy. Expanding into frontline populations would multiply peak sales forecasts, driving substantial high-margin alliance royalties and expanding group operating margins. Probability: +32%. Expected impact: +20%.

What to monitor

Thesis watchpoints

-- Core oncology quarterly revenue sustaining above 14% constant currency through 2027 confirms pipeline replacement velocity offsets Farxiga generic erosion.

Key insights

Free cash flow conversion dropping below 60% of reported operating earnings over two consecutive quarters indicates severe capital misallocation.
Material regulatory sanctions or Chinese revenue deceleration below 2% year-over-year warrants immediate downward revision of terminal multiple assumptions.

Company Financial Analysis

AstraZeneca Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

AstraZeneca's financial trajectory highlights a strong underlying commercial engine transitioning toward high-margin specialty medicine. Fiscal 2025 revenue rose 11% to USD 58.7 billion, and net income reached USD 10.22 billion, supported by robust oncology and rare-disease demand. Trailing twelve-month revenue expanded past USD 61 billion by mid-2026, demonstrating that double-digit volume growth in key cancer therapies has effectively cushioned early pricing pressures on mature cardiovascular lines. However, the composition of these earnings demands careful interpretation. While management's core operating metrics showcase double-digit expansion, reported statutory earnings reflect substantial charges for intangible asset amortization and legal provisions. Free cash flow generation of USD 8.43 billion remains solid, but cash conversion lags adjusted accounting profit due to ongoing launch investments and working capital movements.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 58.7B	USD 10.2B	USD 8.7B
2024	USD 52.9B	USD 6.9B	USD 7.3B
2023	USD 46.6B	USD 6.1B	USD 6.6B
2022	USD 44.3B	USD 3.3B	USD 7.2B
2021	USD 37.1B	USD 109.9M	USD 3.8B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	28.3x	TTM	USD-normalized	GBX / USD
2024	29.1x	TTM	USD-normalized	GBX / USD
2023	35.2x	TTM	USD-normalized	GBX / USD
2022	64.5x	Annual	USD-normalized	GBX / USD
2021	>100x	Annual	USD-normalized	GBX / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profitability trends showcase meaningful structural expansion as the product portfolio shifts toward advanced biologic therapies. Gross margins widened to 81.9% in fiscal 2025, driven by an increasing mix of high-value oncology and rare-disease medicines that carry superior pricing power. Operating margins reached 23.4%, held in check primarily by deliberate increases in late-stage clinical development expenditure rather than underlying operational inefficiency. Sustaining margin expansion toward management's targeted mid-thirties percentage range will face intermediate friction. As patent expirations on Farxiga erode high-margin metabolic sales and statutory US price negotiation caps realized pricing, product mix will encounter temporary drag. Long-term margin progression depends on whether commercial launch volumes can generate sufficient operating leverage across existing sales infrastructure to absorb fixed research overhead.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 13.7B	23.4%	17.4%
2024	USD 12.5B	23.7%	13.0%
2023	USD 9.6B	20.5%	13.0%
2022	USD 5B	11.4%	7.4%
2021	USD 2.8B	7.6%	0.3%

Balance sheet and leverage

AI Review

AstraZeneca's balance sheet reflects steady post-acquisition deleveraging, with the debt-to-equity ratio moderating to 0.61 by fiscal 2025 as total equity expanded to USD 48.7 billion. Net debt stood near USD 26.9 billion through mid-2026, matched by strong operating earnings that provide comfortable interest coverage exceeding eight times. This financial profile ensures solid debt service capacity and preserves access to commercial credit lines. Nevertheless, headline leverage metrics conceal significant ongoing commitments. A substantial portion of the company's USD 114 billion in assets consists of acquired intangible assets that generate recurring non-cash amortization charges. Furthermore, multi-year clinical collaboration milestones and planned manufacturing localization outlays limit balance-sheet flexibility, meaning major debt-funded acquisitions or aggressive share buybacks remain unlikely over the near term.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 29.6B	USD 5.7B	USD 23.9B net debt	0.94x
2024	USD 30.1B	USD 5.6B	USD 24.6B net debt	0.93x
2023	USD 28.4B	USD 5.9B	USD 22.6B net debt	0.81x
2022	USD 29.1B	USD 6.2B	USD 23B net debt	0.86x
2021	USD 30.7B	USD 6.4B	USD 24.4B net debt	1.16x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management maintains an aggressive reinvestment posture, committing USD 14.23 billion to research and development in fiscal 2025, which represents over 24% of annual revenue. Physical capital expenditure absorbed an additional 10% of sales, directed toward state-of-the-art biologics production and automated antibody-drug conjugate manufacturing facilities in Singapore and the United States. This heavy capital deployment prioritizes scientific leadership over short-term accounting optics. This spending intensity reflects the realities of modern biopharmaceutical replacement. Rather than underinvesting to flatter near-term margins, the enterprise is constructing proprietary manufacturing networks and advancing more than one hundred Phase III clinical programs. While this elevated burn rate constrains immediate free cash flow yield, it builds formidable technical barriers that protect long-term returns on invested capital from generic duplication.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 5.9B	USD 14.2B
2024	USD 4.6B	USD 12B
2023	USD 3.8B	USD 10.5B
2022	USD 2.6B	USD 9.6B
2021	USD 2.2B	USD 8.4B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	NEUTRAL	54	+7.7%	Not available	ORIGINAL
5Y	BUY	149	+59.7%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	12,125	12,642.86	13,125	14
+6M	March 18, 2027	11,640	12,830.18	13,650	14
+9M	June 18, 2027	11,407.2	13,038.16	14,059.5	14
+1Y	September 18, 2027	11,521.27	13,183.65	14,481.29	14
+15M	December 18, 2027	11,290.85	13,521.96	14,915.72	14
+18M	March 18, 2028	11,403.76	13,722.9	15,064.88	14
+21M	June 18, 2028	11,631.83	14,012.05	15,666	14
+2Y	September 18, 2028	11,631.83	14,288.26	16,135.98	14
+27M	December 18, 2028	11,748.15	14,617.24	16,620.06	14
+30M	March 18, 2029	11,983.11	14,855.19	16,952.46	14
+33M	June 18, 2029	12,222.77	15,209.46	17,630.56	14
+3Y	September 18, 2029	12,345	15,478.24	17,983.17	14
+39M	December 18, 2029	12,591.9	15,889.69	18,522.66	14
+42M	March 18, 2030	12,843.74	16,170.01	18,893.12	14
+45M	June 18, 2030	12,972.18	16,542.18	19,459.91	14
+4Y	September 18, 2030	13,231.62	16,815.84	19,849.11	14
+51M	December 18, 2030	13,363.94	17,132.59	20,246.09	14
+54M	March 18, 2031	13,497.58	17,431.19	20,448.55	14
+57M	June 18, 2031	13,509.98	17,689.04	20,857.52	14
+5Y	September 18, 2031	13,632.55	17,975	21,274.67	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Frozen comparison context

GBPUSD.FOREX forecast context

The batch's original direct_listing_to_usd path is preserved for transparent interpretation of USD-normalized returns.

FX snapshot: 1.34 on September 20, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 20, 2026	1.3132	1.3237	1.34
+6M	March 20, 2027	1.2869	1.3096	1.3534
+9M	June 20, 2027	1.2741	1.3087	1.3669
+1Y	September 20, 2027	1.2613	1.3116	1.3669
+15M	December 20, 2027	1.2487	1.3089	1.3806
+18M	March 20, 2028	1.2362	1.3071	1.3801
+21M	June 20, 2028	1.2239	1.3128	1.3939
+2Y	September 20, 2028	1.2361	1.3158	1.4078
+27M	December 20, 2028	1.2359	1.3139	1.4078
+30M	March 20, 2029	1.2361	1.309	1.3937
+33M	June 20, 2029	1.2357	1.3128	1.4076
+3Y	September 20, 2029	1.2234	1.3138	1.4081
+39M	December 20, 2029	1.2234	1.3168	1.4222
+42M	March 20, 2030	1.2236	1.3159	1.4222
+45M	June 20, 2030	1.2232	1.3216	1.4364
+4Y	September 20, 2030	1.211	1.3218	1.4507
+51M	December 20, 2030	1.211	1.3189	1.4362
+54M	March 20, 2031	1.1993	1.3198	1.4506
+57M	June 20, 2031	1.2109	1.3236	1.4506
+5Y	September 20, 2031	1.1991	1.3227	1.4506

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The synthesized evidence reveals a clear common pattern: strong organic growth in targeted oncology and rare diseases is colliding with immediate patent expiries on legacy small molecules, notably Farxiga. Multiple reports share the premise that next-generation biologics, particularly antibody-drug conjugates and respiratory therapies, will eventually restore double-digit earnings growth. However, several analyses uncritically project management's eighty-billion-dollar revenue target without discounting partner profit-sharing, statutory US price concessions, or rising clinical capital intensity. The strongest contrarian analyses demonstrate that free cash flow conversion materially lags core accounting profits due to heavy research reinvestment and manufacturing commitments. Factual scrutiny confirms that while commercial replacement velocity is robust, intermediate multiple compression is inevitable as sovereign payers enforce price caps. Consequently, relative weighting prioritizes reports grounded in primary regulatory filings, audited cash flows, and realistic margin structures over those relying on speculative multiple expansion.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight11.1/100

Distinguished by meticulous primary source verification, grounded balance-sheet reconciliation, and granular cash conversion tracking. Accurately decouples headline revenue targets from distributable cash flows while properly accounting for partner economics, US policy agreements, and capital deployment.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight11.1/100

Exhibits superior evidence quality by incorporating recent Phase III readouts, corporate disclosures, executive insider buying, and specific policy agreements. Accurately identifies the divergence between reported IFRS figures and core metrics, grounding cash flow expectations in empirical operational constraints.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight8.3/100

Delivers forensic scrutiny on the gap between core accounting adjustments and statutory cash generation. Accurately maps the timing friction between Farxiga patent cliffs and late-stage respiratory launches, establishing realistic intermediate multiple compression expectations.

AI THINKER

Universal Investor AI

The Polymath

The Titan

Gemini 3.8 Flash

Weight4.6/100

Constructs an extensive pipeline inventory but suffers from overly aggressive multiple expansion assumptions and hyperbolic top-line compounding projections. Downweighted due to excessive optimism regarding simultaneous blockbusters and minimal allowance for standard biopharma clinical attrition.

Skip to references

Research Provenance

References & Context

This AstraZeneca consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 58 deduplicated sources retained for this batch.

01Approval Letter_220359Orig1s000ltr.pdfaccessdata.fda.gov
02Selected Drugs and Negotiated Prices | CMScms.gov
03ASTRAZENECA PLC - Form 6-K - FY2026sec.gov
04ASTRAZENECA PLC - Form 6-K - FY2026sec.gov
05Fact Sheet: President Donald J. Trump Announces Second Deal to Bring Most-Favored-Nation Pricing to American Patientswhitehouse.gov
06AstraZeneca stock gains as Enhertu lung-cancer data offsets SERENA-4 setbackad-hoc-news.de
07AstraZeneca stock gains despite pipeline setbacks and YTD underperformancead-hoc-news.de
08AstraZeneca stock gains on Goldman Sachs target risead-hoc-news.de
09Annual report 2025astrazeneca.com
10AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patientsastrazeneca.com
11AstraZeneca begins trading on the New York Stock Exchangeastrazeneca.com
12AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&Dastrazeneca.com
13Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertensionastrazeneca.com
14Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancerastrazeneca.com
15H1 and Q2 2026 resultsastrazeneca.com

And 43 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-12-31–2026-06-30, 12 periods

Currencies cited: GBP, GBX, USD (quote GBX; primary reporting USD; converted/valuation USD; normalization GBP).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.